Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar

A technology of antibody conjugates and calicheamicin, applied in the direction of antibody medical ingredients, medical preparations containing active ingredients, organic active ingredients, etc., can solve the problems that cannot be determined in advance, the efficacy is reduced, and the PK interaction is unpredictable And other issues

Inactive Publication Date: 2008-09-03
KANISA PHARMA INC
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, PK interactions are unpredictable and cannot be predetermined
Thus, serum levels of cytotoxic agents are either too high, resulting in excess toxicity, or too low, resulting in reduced potency

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
  • Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0039] DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

[0040] The following description and examples illustrate preferred embodiments of the invention in detail. Those skilled in the art will recognize that several variations and modifications of the invention may be made within the scope of the present application. Therefore, the description of preferred embodiments should not be considered as limiting the scope of the invention.

[0041] cancer target

[0042] Many forms of cancer express P-gp and thus may benefit from the administration of inhibitors of P-gp efflux pumps when treated with chemotherapeutic agents that are substrates of P-gp efflux. For example, most solid tumors, lymphomas, bladder cancers, pancreatic cancers, ovarian cancers, liver cancers, myelomas, and sarcomas are cancers that express greater than 50% of P-gp. Lymphoblastic leukemia also has greater than 50% P-gp expression. P-gp expression in breast cancer is about 30%. For metastatic breast can...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to a method of treating patients with solid tumors, leukemias, and other malignancies using a combination of zosuquidar and a calicheamicin-antibody conjugate, such as Mylotarg. The invention is also directed to pharmaceutical formulations comprising zosuquidar and calicheamicin-antibody conjugates. The formulations are particularly effective in treating relapsed Acute Myelogenous Leukemia (AML) and metastatic breast cancer.

Description

[0001] related application [0002] This application claims U.S. Provisional Application No. 60 / 696,756, filed July 6, 2005, U.S. Application No. 11 / 416,833, filed May 3, 2006, and U.S. Application No. 11 / 416,992, filed May 3, 2006 Yes, the entire content of the above application is hereby incorporated by reference and is hereby made part of this specification. field of invention [0003] The present invention relates to the treatment of patients with solid methods for patients with tumors, leukemias, and other malignancies. The invention also relates to pharmaceutical formulations containing zosuquidar and calicheamicin-antibody conjugates. The formulations are particularly effective in the treatment of relapsed acute myeloid leukemia (AML). Background of the invention [0004] The field of oncology is undergoing major developments. In the past, cancer treatment has been dominated by empirical, "one-size-fits-all" treatments based on tumor type and stage. Despite extre...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/00
CPCA61K39/39558A61K31/4709A61K2300/00
Inventor 布拉尼米尔·西基奇丹尼尔·霍特戴维·索克斯斯科特·格莱恩约翰·马尔切莱蒂迈克尔·J·沃尔什普拉蒂克·S·穆尔塔尼
Owner KANISA PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap